Sign in
Taking people in United StatesNo phase

Testing people for gene changes linked to cancer risk

Checks people for KRAS and other microRNA binding gene changes in an observational study.

Key facts

Who runs it
MiraKind
Where
Los Angeles, United StatesSee the site
Trial code
Registry title
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Status
Recruiting
People taking part
15,000 people, planned
Started
Sept 2014
Expected to end
Sept 2035
Type of study
Observational, 4 groups
Treatments tested
  • KRAS-variant and microRNA binding site mutation testing
Record updated
23 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a personal or family history of cancer, or a personal history of endometriosis or autoimmunity. Participants may have the KRAS-variant or other microRNA binding site mutations.

Age
18 years and older
Sex
All sexes can join.
Biomarker or test result
Testing for the KRAS-variant and other microRNA binding site mutations.

Main reasons for not taking part

  • Younger than 18
  • Non-English speaking and unable to understand and sign the consent

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Personal or family history of cancer
  • Personal history of endometriosis, or autoimmunity

Who cannot take part

  • Younger than 18
  • Non-english speaking and unable to understand and sign the consent

Where in United States

  • MiraKindLos Angeles, United StatesContact: Joanne Weidhaas, MDPhDTaking people

About the trial

What the trial wants to find out

The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.

The 4 groups in the trial

  • Family Registry

    For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.

    Treatment: KRAS-variant and microRNA binding site mutation testing

  • Double primary breast cancer

    Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.

    Treatment: KRAS-variant and microRNA binding site mutation testing

  • Autoimmunity

    We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.

    Treatment: KRAS-variant and microRNA binding site mutation testing

  • Cancer patients receiving certain treatments

    We have found that microRNA binding site mutations are predictive biomarkers of outcomes from cancer therapy, including response and toxicity. We will enroll patients to further study and validate these findings.

    Treatment: KRAS-variant and microRNA binding site mutation testing

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Plain-language title
Testing people for gene changes linked to cancer riskGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 January 2025